1. Scrip
  2. >>R&D
  3. >>Clinical Trials

NuCana Investigates Why Colorectal Cancer Study Failed

 
• By Alaric DeArment

Patients in the NUC-3373 arm had a worse prognosis than those in the control arm, but the company is looking at the combination with irinotecan as the potential culprit.

• Source: Shutterstock

NuCana plc is working on some hypotheses about why its Phase II NuTide:323 study of NUC-3373 in colorectal cancer was unsuccessful, including prognostic factors in the study arm versus the control arm or the combination with one of the chemotherapy agents. But the culprit does not appear to be NUC-3373 itself.

Edinburgh, UK-based NuCana said on 29 August that it would discontinue NuTide:323 after a preplanned initial analysis and recommendation from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

More from R&D

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.